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apicoplast, which houses essential metabolic pathways and is required throughout the parasite 23 life cycle. Hundreds of proteins are imported across 4 membranes into the apicoplast to support 24 its function and biogenesis. The machinery that mediates this import process is distinct from 25 proteins in the human host and may serve as ideal drug targets. However, a significant concern is 26 whether inhibition of apicoplast protein import will result in a "delayed-death" phenotype that 27 limits clinical use, as observed for inhibitors of apicoplast housekeeping pathways. To assess the 28 growth inhibition kinetics of disrupting apicoplast protein import, we targeted a murine 29 dihydrofolate reductase (mDHFR) domain, which is stabilized by the compound WR99210, to 30 the apicoplast to enable inducible blocking of apicoplast-localized protein translocons. We show 31 that stabilization of this apicoplast-targeted mDHFR disrupts parasite growth within a single lytic 32 cycle in an apicoplast-specific manner. Consistent with inhibition of apicoplast protein import, 33 stabilization of this fusion protein disrupted transit peptide processing of endogenous apicoplast 34 proteins and caused defects in apicoplast biogenesis. These results indicate that disruption of 35 apicoplast protein import avoids delayed-death growth inhibition and that target-based 36 approaches to develop inhibitors of import machinery may yield viable next-generation 37 antimalarials. 38 Importance: Malaria is a major cause of global childhood mortality. To sustain progress in 39 disease control made in the last decade, new antimalarial therapies are needed to combat 40 emerging drug resistance. Malaria parasites contain a relict chloroplast called the apicoplast, 41 which harbors new targets for drug discovery, including import machinery that transports 42 hundreds of critical proteins into the apicoplast. Unfortunately, some drugs targeting apicoplast 43 Introduction 51
Plasmodium spp. parasites cause malaria and are responsible for over 200 million human 52 infections and over 400,000 deaths annually (1). Despite a reduction in malaria-related mortality 53 in the past 15 years, emerging resistance to frontline antimalarials necessitates the continued 54 development of new chemotherapies (2, 3). One key source of drug targets is the apicoplast, a 55 nonphotosynthetic plastid organelle found in many apicomplexan pathogens (4, 5). The 56 apicoplast produces essential metabolites required for parasite replication (6). Apicoplast 57 function requires the import of over 300 nuclear-encoded gene products into the organelle, 58
including biosynthetic enzymes and pathways that support organelle biogenesis and maintenance 59 (7) . Most apicoplast proteins are 1) synthesized on cytosolic ribosomes, 2) trafficked to the 60 apicoplast via the endoplasmic reticulum (ER), and 3) translocated across the 4 apicoplast 61 membranes. This multistep import pathway involves more than a dozen proteins, including 62 homologs of the translocation and ubiquitylation machinery typically involved in ER-associated 63 degradation (ERAD) (8-12) as well as homologs of the TOC and TIC machinery found in plant 64 plastids (9, (13) (14) (15) . 65
Apicoplast protein import machinery are potential drug targets, but a key unresolved 66 question is whether inhibition of apicoplast protein import causes a "delayed-death" phenotype 67 that has been observed for inhibitors of apicoplast housekeeping functions (16, 17) . During 68 delayed death, parasite growth is unaffected during the first lytic cycle of inhibitor treatment but 69 is severely inhibited in the second lytic cycle even after drug removal. This in vitro phenotype 70 manifests as a slow onset-of-action that limits clinical use of these drugs. Unfortunately, there 71 are no inhibitors known to act directly on apicoplast protein import, precluding direct assessment 72 of growth inhibition kinetics. Furthermore, most genetic tools available in Plasmodium parasites 73 act at the DNA or RNA levels (18), which can result in different growth inhibition kinetics than 74 direct chemical inhibition of that same target (19) (20) (21) . Destabilization domains that conditionally 75 target proteins for degradation by the cytosolic ubiquitin-proteasome enable protein-level 76 disruption (22, 23), but these systems are not suitable to study apicoplast-localized proteins, 77 which are inaccessible to the cytosolic proteasome. 78
Given these limitations, we developed a protein-level tool to dissect growth inhibition 79 kinetics following disruption of apicoplast protein import. A murine dihydrofolate reductase 80 (mDHFR) domain which can be conditionally stabilized by a small molecule has been used to 81 characterize protein translocation steps during yeast mitochondrial protein import in vitro (24) 82 and, more recently, during export of malarial proteins across the parasitophorous vacuole (PV) 83 membrane into the host red blood cell (25, 26) . Strikingly, in the context of malarial protein 84 export, mDHFR stabilized with the compound WR99210 can block the translocon to prevent 85 export of other Plasmodium proteins and disrupt parasite growth (27) . Given that there are at 86 least three putative translocation steps during apicoplast protein import (7), we reasoned that we 87 could use a similar strategy to block apicoplast translocons and disrupt protein import in a 88 manner that resembles inhibition with a small molecule ( Fig. 1A) . 89 90
Results and Discussion 91
To generate a protein-level conditional tool for disruption of apicoplast protein import, we 92 targeted a GFP-mDHFR fusion to the apicoplast via the N-terminal leader sequence of acyl 93 carrier protein (ACP) ( Fig. 1B) . As a negative control, we generated a cell line expressing the 94 same fusion with a lysine 18 to glutamate (K18E) mutation in the ACP leader sequence that 95 renders this transit peptide nonfunctional and causes mistargeting to the PV (28). Both GFP-96 mDHFR fusions were expressed in P. falciparum Dd2 attB parasites (29) and localized to the 97 expected compartments (Fig. 1C ). 98
To test whether stabilization of these GFP-mDHFR fusions disrupted parasite growth, we 99 treated ring-stage parasites with increasing doses of WR99210 and assessed parasitemia after 3 100 days as a read-out for parasite growth inhibition during the first lytic cycle. Parental Dd2 attB 101 parasites, which express a WR99210-resistant human DHFR allele, were unaffected at the 102 WR99210 concentrations tested ( Fig. 2A ). Parasites expressing the PV-localized ACPL(K18E)-103 GFP-mDHFR fusion from the attB site were also insensitive to WR99210. In contrast, parasites 104 expressing the apicoplast-targeted ACPL-GFP-mDHFR fusion showed dose-dependent growth 105 inhibition in response to WR99210 ( Fig. 2A) . 106
During in vitro culture of blood-stage P. falciparum, biosynthesis of the isoprenoid 107 precursor isopentenyl pyrophosphate (IPP) is the only essential function of the apicoplast. As 108 such, supplementation with exogenous IPP can rescue apicoplast defects and can be used to 109 identify apicoplast-specific phenotypes (30). IPP supplementation reversed the WR99210 110 sensitivity of parasites expressing ACPL-GFP-mDHFR in both a 3-day dose-response experiment 111 and over a 5-day time course ( Fig. 2A and B) . These results indicate that the WR99210 112 sensitivity conferred by ACPL-GFP-mDHFR is due to disruption of an apicoplast-specific 113 pathway. 114
Given our hypothesized mechanism-of-action inhibiting apicoplast protein import ( Fig.  115 1A), we expected that ACPL-GFP-mDHFR stabilization would cause global disruption of the 116 apicoplast, including organelle maintenance and biogenesis, leading to apicoplast loss. To assess 117 the status of the apicoplast, we assayed the presence of the apicoplast genome in WR99210-118 treated, IPP-rescued parasites by quantitative PCR (qPCR). WR99210 treatment caused a 119 decrease in the apicoplast:nuclear genome ratio beginning at 1 day post-treatment and near-120 complete loss of the apicoplast genome after 2 lytic cycles (Fig. 3) . The loss of the apicoplast 121 genome, a key marker of the apicoplast, indicates that chemical stabilization of ACPL-GFP-122 mDHFR-expressing parasites caused apicoplast loss. 123
Sorting of apicoplast cargo occurs in the parasite endomembrane system, after which 124 proteins are thought to traffic to the apicoplast by vesicle transport. While we expected that 125 stabilization of ACPL-GFP-mDHFR would disrupt transit of apicoplast cargo across the 126 apicoplast-localized ERAD-and TOC/TIC translocons, there was a possibility that this stabilized 127 fusion protein could disrupt the upstream sorting process and prevent apicoplast proteins from 128 ever reaching the organelle. Previous data suggest that defects in sorting apicoplast cargo 129 manifest as mistargeting of apicoplast proteins to the PV (28). To assess whether stabilization of 130 ACPL-GFP-mDHFR blocked protein import early during sorting or later after arrival at the 131 apicoplast, we used live-and fixed-cell imaging to assess whether this fusion protein and the 132 endogenous apicoplast protein ACP were successfully sorted in WR99210-treated parasites. As 133 expected, in untreated parasites ACPL-GFP-mDHFR localized to an elongated structure 134 characteristic of the apicoplast and co-localized with ACP ( Fig. 4A and B ). After 1 day of 135 WR99210 treatment (i.e., within the same lytic cycle as treatment), the majority of cells 136 exhibited ACPL-GFP-mDHFR and ACP signal in a single punctum or elongated pattern that 137 likely indicates an intact apicoplast ( Fig. 4A and B) . After 3 days of WR99210 treatment (i.e., 138 after 1 full lytic cycle of treatment), both ACPL-GFP-mDHFR and ACP were present almost 139 exclusively in diffuse puncta that are thought to represent vesicles post-sorting in parasites that 140 have lost their apicoplast (30) ( Fig. 4A and B) . Altogether, the localization of ACPL-GFP-141 mDHFR and ACP to either organelle-like structures or diffuse puncta following mDHFR 142 stabilization indicates that sorting in the parasite endomembrane system remained intact. This 143 suggests that the defect in WR99210-treated ACPL-GFP-mDHFR parasites occurs after this 144 initial protein sorting step. 145
Most apicoplast-targeted proteins contain an N-terminal transit peptide that is 146 proteolytically processed upon successful import into the organelle lumen, and an accumulation 147 of unprocessed protein can be used as a marker for a protein import defect. We expected that 148 stabilized ACPL-GFP-mDHFR would block translocation of apicoplast cargo into the organelle 149 lumen and cause a transit peptide processing defect in WR99210-treated parasites. We therefore 150 assessed the processing of the ACPL-GFP-mDHFR fusion and the endogenous apicoplast protein 151
ClpP by western blotting. Consistent with a defect in protein translocation, WR99210-treated 152 parasites exhibited a modest but reproducible accumulation of unprocessed ACPL-GFP-mDHFR 153 after 1 day of WR99210 treatment ( Fig. 4C and D) . ClpP showed a comparable transit peptide 154 processing defect ( Fig. 4C and D) , suggesting that stabilization of ACPL-GFP-mDHFR affected 155 import not only of the fusion protein itself but also of endogenous apicoplast cargo. Processing 156 of both the GFP-mDHFR fusion and ClpP was almost completely ablated after 3 days of 157 WR99210 treatment ( Fig. 4C and D) . Because apicoplast proteins are still sorted to the 158 apicoplast ( Fig. 4A and B) but show a transit peptide processing defect ( Fig. 4C and D) , these 159 data are consistent with a disruption in the translocation of apicoplast proteins across one or 160 more apicoplast membranes. 161
In lieu of direct inhibitors of apicoplast protein import, we used a chemical biology 162 approach to conditionally block apicoplast protein import by addition of a small molecule. 163
Altogether, our results suggest a model in which chemically stabilized ACPL-GFP-mDHFR 164 traffics to the apicoplast and stalls within putative membrane translocons, preventing import of 165 endogenous apicoplast cargo and disrupting apicoplast biogenesis and function. Given that 166 apicoplast protein import is likely required for biogenesis pathways such as apicoplast genome 167 replication, the emergence of both a transit peptide processing defect (a readout for protein 168 import; Fig. 4C and D) and a genome replication defect (Fig. 3 ) after 1 day of ACPL-GFP-169 mDHFR stabilization are consistent with this model. Unfortunately, because we could not detect 170 direct biochemical interaction of stabilized ACPL-GFP-mDHFR with apicoplast translocons, we 171 cannot rule out translocation-independent mechanisms-of-action, such as toxicity due to 172 accumulation of stably folded ACPL-GFP-mDHFR in the apicoplast lumen. However, given the 173 previous uses of mDHFR fusions to block protein translocation (24-27) and the defect in 174 apicoplast protein import observed after just 1 day of WR99210 treatment ( Fig. 4C and D ), our 175 model seems the most parsimonious. 176
These findings suggest that the proteins required for apicoplast protein import can serve 177 as antimalarial targets that avoid delayed-death growth inhibition. Over a dozen proteins have 178 been implicated in import of nuclear-encoded apicoplast proteins, but of particular interest are 179 proteins related to established drug targets in other systems. For example, the apicoplast-180 localized AAA ATPase CDC48 is related to mammalian p97 and is likely involved in 181 translocation of apicoplast cargo across the periplastid membrane (12). Notably, mammalian 182 p97, which plays an important role in ERAD and other cellular processes, is of interest as an 183 anti-cancer drug target. Specific inhibitors of mammalian p97 have been developed (31-34), 184 suggesting that the same could be accomplished for the apicoplast-localized CDC48 in 185 apicomplexans. Similarly, components of an apicoplast-localized ubiquitylation system are 186 essential for apicoplast protein import and may also represent potential drug targets (11) 
Vector construction 211
Oligonucleotides (Table 1) For live imaging, parasites were settled onto glass-bottomed microwell dishes (MatTek P35G-232 1.5-14-C) in PBS containing 0.4% glucose and 2 μg/mL Hoechst 33342 stain (ThermoFisher 233 H3570). 234
For fixed imaging, parasites were processed as previously described (40) washed once with PBS, permeabilized in 0.1% Triton X-100 in PBS for 10 minutes, and washed 240 twice more in PBS. Coverslips were treated with 0.1 mg/mL sodium borohydride in PBS for 10 241 minutes, washed once in PBS, and blocked in 5% BSA in PBS. Following blocking, parasites 242 were stained with 1:500 rabbit-α-PfACP (41) diluted in 5% BSA in PBS overnight at 4°C. 243
Coverslips were washed three times in PBS, incubated for 1 hour in 1:3000 donkey-α-rabbit 568 244 secondary antibody (ThermoFisher A10042) in 5% BSA in PBS, washed three times in PBS, 245 mounted onto slides with ProLong Gold antifade reagent with DAPI (ThermoFisher P36935), 246 and sealed with nail polish prior to imaging. 247
Cells were imaged with a 100X, 1.35 NA objective on an Olympus IX70 microscope 248 with a DeltaVision system (Applied Precision) controlled with SoftWorx version 4.1.0 and 249 equipped with a CoolSnap-HQ CCD camera (Photometrics). Brightness and contrast were 250 adjusted in Fiji (ImageJ) for display purposes. 251 252
Parasite growth assays 253
For dose-response assays, sorbitol-synchronized ring-stage parasites were grown in 96-well 254 plates containing 2-fold serial dilutions of WR99210 (Jacobus Pharmaceutical Company). After 255 3 days of growth, parasites were fixed in 1% paraformaldehyde in PBS and were stained with 50 256 nM YOYO-1 Iodide (ThermoFisher Y3601). Parasitemia was analyzed on a BD Accuri C6 flow 257 cytometer. Each biological replicate of dose-response assays was performed in technical 258
triplicate. 259
For time course growth experiments, sorbitol-synchronized parasites were untreated or 260 were grown with 10 nM WR99210 with or without 200 μM IPP (Isoprenoids, LLC) for 5 days. 261
Cultures were treated identically in terms of media changes and splitting into fresh erythrocytes. 262
Samples to assess growth were collected daily, fixed in 1% paraformaldehyde in PBS, and stored 263 at 4°C until completion of the experiment. Samples were then stained with YOYO-1 and 264 analyzed as above. Tween 20. Blots were incubated with primary antibody at 4°C overnight at the following 288 dilutions: 1:20,000 mouse-α-GFP JL-8 (Clontech 632381); 1:4000 rabbit-α-PfClpP (42); 289 1:20,000 rabbit-α-PfAldolase (Abcam ab207494). Blots were washed once in TBST and were 290 incubated for 1 hour at room temperature in 1:10,000 dilutions of IRDye 800CW donkey-α-291 rabbit or IRDye 680LT goat-α-mouse secondary antibodies (LI-COR Biosciences). Blots were 292 washed three times in TBST and once in PBS before imaging on a LI-COR Odyssey imager. 293 Brightness/contrast adjustments were not held constant between the two cell lines due to 473 differences in GFP fluorescence intensity in the apicoplast versus the PV. Scale bars, 5 µm. 474 
